Table 2 Comparison of drug use between the two groups.
Type 2 diabetes with MCI | Type 2 diabetes without MCI | P value | FDR | |
|---|---|---|---|---|
Number of patients | 71 | 69 | ||
The use of insulin (%) | 47(66.20) | 41(59.42) | 0.407 | 0.930 |
Oral hypoglycemic drugs (%) | 43(60.56) | 48(69.57) | 0.264 | 1 |
Biguanides (%) | 34(47.89) | 40(57.97) | 0.232 | 1 |
a-Glucosidase inhibitor (%) | 33(46.48) | 36(52.17) | 0.500 | 1 |
Sulfonylureas (%) | 12(16.90) | 14(20.29) | 0.606 | 0.808 |
Nateglinide or repaglinide (%) | 10(14.08) | 11(15.94) | 0.758 | 0.809 |
Thiazolidinediones (%) | 5(7.04) | 4(5.80) | 1.000 | 1 |
Antihypertensive medications (%) | 46(64.79) | 39(56.52) | 0.317 | 1 |
Angiotensin-converting enzyme inhibitors (%) | 15(21.13) | 10(14.49) | 0.306 | 1 |
Angiotensin II receptor blockers (%) | 19(26.76) | 22(31.88) | 0.505 | 0.898 |
b-Blockers (%) | 10(14.08) | 12(17.39) | 0.591 | 0.860 |
Calcium channel blockers (%) | 22(31.00) | 19(27.54) | 0.654 | 0.805 |
Diuretics (%) | 13(18.31) | 11(15.94) | 0.710 | 0.811 |
a1-Blockers (%) | 4(5.63) | 1(1.45) | 0.366 | 1 |
Antiplatelet medications (%) | 41(57.75) | 35(50.72) | 0.404 | 1 |
Lipid-lowering medications (%) | 45(63.38) | 40(57.97) | 0.512 | 0.819 |
